

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A composition comprising:  
a supporting body,  
a non-liquid medicine storage layer comprising one or more medicine(s) that  
permeate, dissolve, disperse or diffuse into a plasticized permeation control film which has  
been activated by moisture, wherein the solid medicine storage layer consists of the  
medicine(s) or consists of the medicine(s) and a vehicle,  
a permeation controlling film, which is a water soluble polymer, that is plasticized  
when activated by moisture from the skin and that permits the permeation of the medicine(s)  
out of the medicine storage layer when plasticized,  
a layer of an adhesive comprising an acrylic adhesive and/or a rubber type adhesive,  
and  
a release liner.

Claim 2-4 (Cancelled):

Claim 5 (Currently Amended): The composition according to Claim 1 Claim 4 that  
comprises a medicine that is water-soluble.

Claim 6 (Currently Amended): The composition according to Claim 1 Claim 4 that  
comprises a vehicle that is a water-disintegrative substance.

Claim 7 (Previously Presented): The composition according to Claim 1 comprising a supporting body that has a water-vapor permeability of 100 g/m<sup>2</sup> or less at the condition of 40°C and 24 hours.

Claim 8 (Previously Presented): The composition according to Claim 1 that comprises an adhesive that has a water-vapor permeability of 100g/m<sup>2</sup> or more at the condition of 40°C and 24 hours.

Claim 9 (Previously Presented): The composition according to Claim 1 that comprises a medicine that is nicorandil, dopamine hydrochloride or eperisone hydrochloride.

Claims 10-18 (Cancelled):

Claim 19 (Previously Presented): The composition of Claim 1 that comprises a medicine storage layer comprising one or more cardiotonic drug(s).

Claim 20 (Previously Presented): The composition of Claim 1 that comprises a medicine storage layer comprising one or more vasodilator(s).

Claims 21-31 (Cancelled):

Claim 32 (Previously Presented): The composition of Claim 1 that comprises a medicine storage layer comprising one or more medicine(s) and one or more vehicle(s) or excipient(s).

Claim 33 (Previously Presented): The composition of Claim 32 comprising one or more vehicle(s) or excipient(s) that are water-disintegrative substances.

Claim 34 (Previously Presented): The composition of Claim 1 further comprising a medicine storage layer comprising one or more additive(s) or absorption accelerator(s), or both.

Claim 35 (Previously Presented): A method for administering one or more medicine(s) comprising applying the composition of Claim 1 to the skin of a subject for a time and under conditions suitable for percutaneous absorption of said medicine(s).

Claim 36 (Currently Amended): A method for making the composition of Claim 1 comprising:

attaching or laminating together:  
a supporting body,  
a non-liquid medicine storage layer comprising one or more percutaneously absorbable medicine(s) that permeate, dissolve, disperse or diffuse into a plasticized permeation control film which has been activated by moisture, wherein the solid medicine storage layer consists of the medicine(s) or consists of the medicine(s) and a vehicle,  
a permeation controlling film that is plasticized when activated by moisture from the skin and that permits the permeation of the medicine(s) out of the medicine storage layer when plasticized,  
a layer of an adhesive and  
a release liner.

Application No. 09/762,615  
Reply to Office Action of August 4, 2003

Claim 37 (Previously Presented): The composition according to Claim 1 that comprises a permeation controlling film that is poly(vinyl alcohol) and a medicine that is nicorandil, dopamine hydrochloride or eperisone hydrochloride.

Claim 38 (Previously Presented): The composition according to Claim 1 that comprises a permeation controlling film that is poly(vinyl alcohol) and a medicine that is nicorandil.